<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    DURECT Corporation

    DURECT Corporation

    DURECT is a biopharmaceutical company actively developing therapeutics based on it...

    DURECT is a biopharmaceutical company actively ...

    Filing Type:    PU
    Caladrius Biosciences, Inc.

    Caladrius Biosciences, Inc.

    Caladrius is a clinical-stage biopharmaceutical company committed to the developme...

    Caladrius is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    ESSA Pharma Inc.

    ESSA Pharma Inc.

    With a focus on the development of small molecule drugs for the treatment of cance...

    With a focus on the development of small molecu...

    Filing Type:    PU
    Ascendis Pharma A/S

    Ascendis Pharma A/S

    Ascendis Pharma is applying its innovative technology platform to build a leading,...

    Ascendis Pharma is applying its innovative tech...

    Filing Type:    PU
    Vascular Biogenics Ltd.

    Vascular Biogenics Ltd.

    VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharm...

    VBL Therapeutics is a publicly traded (NASDAQ: ...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.